Skip to content
Axcess News – Lifestyle
Author:
Lumanity
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
August 14, 2026
Lumanity Strengthens Climate Commitment with SBTi (Science Based Targets Initiative) Validation for Near-Term Emissions Reduction Targets
July 7, 2026
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
May 21, 2026
Lumanity Launches EMULaiTOR™, an AI-Powered Synthetic Persona Platform Transforming Stakeholder Engagement in Life Sciences
March 5, 2026